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G E N E T I C S
Linking the FTO obesity rs1421085 variant circuitry 
to cellular, metabolic, and organismal phenotypes 
in vivo
Samantha Laber1,2,3,4,5*†, Sara Forcisi6,7*†, Liz Bentley1, Julia Petzold8, Franco Moritz6, 
Kirill S. Smirnov6, Loubna Al Sadat7,9, Iain Williamson10, Sophie Strobel4,8, Thomas Agnew1‡, 
Shahana Sengupta1, Tom Nicol1§, Harald Grallert7,11, Margit Heier12,13, Julius Honecker9, 
Joffrey Mianne14, Lydia Teboul14, Rebecca Dumbell1‖, Helen Long1,15, Michelle Simon1, 
Cecilia Lindgren3,16,17,18, Wendy A. Bickmore10, Hans Hauner7,8,9, Philippe Schmitt-Kopplin6,7,19, 
Melina Claussnitzer4,5,20*†, Roger D. Cox1*†
Variants in FTO have the strongest association with obesity; however, it is still unclear how those noncoding 
variants mechanistically affect whole-body physiology. We engineered a deletion of the rs1421085 conserved 
cis-regulatory module (CRM) in mice and confirmed in vivo that the CRM modulates Irx3 and Irx5 gene expression 
and mitochondrial function in adipocytes. The CRM affects molecular and cellular phenotypes in an adipose 
depot–dependent manner and affects organismal phenotypes that are relevant for obesity, including decreased 
high-fat diet–induced weight gain, decreased whole-body fat mass, and decreased skin fat thickness. Last, we 
connected the CRM to a genetically determined effect on steroid patterns in males that was dependent on nutri-
tional challenge and conserved across mice and humans. Together, our data establish cross-species conservation 
of the rs1421085 regulatory circuitry at the molecular, cellular, metabolic, and organismal level, revealing previously 
unknown contextual dependence of the variant’s action.
INTRODUCTION
The FTO locus has been reproducibly associated with body mass 
index (BMI) in humans across diverse ethnicities (1–3). Like the 
vast majority of trait-associated variants identified by genome-wide 
efforts, BMI-associated variants at the FTO locus map to the non-
coding genome, which is still poorly characterized. In addition, 
genome-wide association study (GWAS) loci characteristically con-
tain dozens of statistically significant variants in high linkage dis-
equilibrium (LD), with regulatory variants often acting at distances 
up to a megabase (Mb), thus implicating multiple potential effector 
genes. These confounding factors pose a major challenge when 
translating genetic associations to mechanisms and therapeutic 
hypotheses. It has recently been shown that FTO intronic regions 
form functional connections to IRX3 and IRX5 (4–6), an Mb away, 
suggesting that variants within FTO could also affect gene regulato-
ry mechanisms at a long distance. The risk allele at the rs1421085 
variant in the FTO locus has been connected to cellular consequences 
in adipocytes and to cellular phenotypes that are relevant for obe-
sity (4). Furthermore, multiple variants and tissues, including both 
adipose and brain, have been implicated in mediating risk at the 
FTO locus, pointing toward multiorgan and multivariant mecha-
nisms (4, 6–9).
To date, it is unclear whether rs1421085—independently of cor-
related neighboring variants—affects an organismal or metabolic 
phenotype. Because gene expression is context specific, variants 
often depend on specific in vivo stimuli, such as nutritional chal-
lenges, to exert their individual effects (10). Model organisms have 
the potential to allow investigation of the spatiotemporal functional 
effects of variants and their target genes in relevant cell types and 
tissues in the whole-body context, linking genetic variation with 
in vivo metabolic physiology. Although the potential for modeling 
human regulatory variation in mice strongly depends on the con-
servation of functional elements between human and mouse, there 
are many good examples of modeling human enhancers and their 
function in the mouse, such as the recent mechanistic analysis of the 
distal enhancer at a human autoimmune and allergic disease risk 
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locus (11q13.5), involved in immune regulatory T (Treg) cell function 
in the suppression of colitis (11). Noncoding regions of the FTO- IRX 
locus show a notable degree of evolutionary sequence conservation 
between mouse and human that places them among the top 2% of 
comparably sized genomic regions (6). Furthermore, studies com-
paring the human regulatory landscape to their murine ortholog have 
yielded new insight into mechanisms involved in diabetes and obesity, 
and cross-species conservation-based computational models have 
successfully been exploited in prioritizing functional regulatory ele-
ments that associate with metabolic diseases (8, 12, 13).
The aim of this study was to recapitulate the FTO rs1421085 reg-
ulatory circuitry at the whole organismal level using a mouse model 
that harbors a mutation at the murine orthologous region flanking 
the human rs1421085 C/T variant. Building on conservation pat-
terns of the regulatory landscape between human and mouse, we 
confirm previous results reporting Irx3 and Irx5 to be target genes 
of the rs1421085 cis-regulatory module (CRM) in adipocyte pro-
genitors (4). In addition, we also reveal a complex context-dependent 
effect on Irx3 and Irx5 target gene regulation, on fat mass and skin 
fat thickness, and on metabolic consequences under high-fat diet 
(HFD) conditions. For the latter, we test the effects of the rs1421085 
circuitry on metabolic murine phenotypes under HFD conditions 
using untargeted, ultrahigh-resolution metabolome analysis and 
show an rs1421085-specific disruption of steroidal metabolic 
homeostasis. We recover an rs1421085 steroid metabotype (14) 
(metabolic phenotype) in human blood plasma samples following an 
oral glucose tolerance test (OGTT) in 379 healthy, normal- weight 
individuals.
RESULTS
rs1421085 is within a regulatory region conserved across 
human and mouse
To develop a murine model system to recapitulate and validate the 
rs1421085 regulatory circuitry at the organismal level, we first as-
sessed the evolutionary conservation of chromatin structure across 
humans and mice at the FTO/Fto locus. In human adipocyte pro-
genitor cells, the BMI association signal in FTO, and more specifi-
cally the regulatory variant rs1421085, is within a region decorated 
by enhancer-associated histone marks (H3K4me1 and H3K27ac; 
Fig.  1). Cross-species analysis revealed that the peaks for histone 
modifications associated with regulatory activity in human preadi-
pocytes were also present in mouse preadipocytes [Fig. 1 and fig. S1 
(FTO/Fto gene zoomed inset)], suggesting a functionally conserved 
regulatory region surrounding rs1421085.
To test whether the physical environment of proximal and distal 
target genes are conserved across human and mouse at the FTO lo-
cus, we examined HiC data surrounding FTO/Fto. In human and 
mouse embryonic stem cells (ESCs) (15), we observed topologically 
associated domains (TADs) (16, 17) that encompassed the same five 
candidate target genes Rpgrip1l, Fto, Irx3, Irx5, and Irx6 in both hu-
man and mouse (Fig. 1). Last, we performed sequence-level analysis 
of the rs1421085 surrounding region and observed that transcrip-
tion factor binding site (TFBS) motifs are well conserved at the 
nucleotide level, including the ARID motif, which was previously 
shown to be disrupted by rs1421085 (4). Together, these data sug-
gest that rs1421085, and more generally the human FTO risk locus, 
localizes within a regulatory element that is conserved at the se-
quence and chromatin structure level.
Deletion of the conserved rs1421085 CRM in mice affects 
body composition
To dissect the mechanism and physiological role of rs1421085, we 
used CRISPR/Cas9 genome editing (18) to delete the rs1421085 
orthologous CRM (rs1421085-DEL82) in the mouse. Specifically, 
rs1421085-DEL82 harbors a homozygous mutation in the ortholo-
gous region between human and mouse, deleting 2 nucleotides (nt) 
upstream and 79 nt downstream of rs1421085 (Fig. 2A), spanning 
the ARID motif. None of the other correlated variants of the 
FTO risk haplotype localizes within these 82 nt. To test whether 
rs1421085-DEL82 affects whole-body composition, we examined 
mutants versus controls under HFD and low-fat diet (LFD) condi-
tions. We observed that homozygous male rs1421085-DEL82 mice 
on an HFD showed a subtle reduction in body weight and fat mass 
from 14 weeks of age (Fig. 2, B and C), which was statistically signif-
icant between 14 and 18 weeks of age for body weight (P < 0.05; 
Fig. 2B) and 14 and 16 weeks of age (P < 0.05; Fig. 2C) for fat mass. 
Lean mass was not altered between genotypes (Fig. 2D). Heterozy-
gous rs1421085-DEL82 had an intermediate effect on body weight 
(fig. S2A) and fat mass gain (fig. S2B) on HFD compared to homo-
zygous alleles, suggesting a dose-dependent effect of the rs1421085-
DEL82 allele on body weight regulation and obesity development in 
male animals. Mice on an LFD did not present with altered body 
weight or fat mass (Fig. 2, B and C). The rs1421085-DEL82 muta-
tion did not have a detectable effect on body weight or fat mass in 
female animals (fig. S3, A to C, E and F), and rs1421085-DEL82 had 
no effect on glucose tolerance in any of the groups (figs. S2, C and 
D, and S3D).
To further investigate the effect on obesity-related phenotypes, 
we examined the effect of rs1421085-DEL82 on subcutaneous der-
mal adipose tissue (sc-dWAT). We quantified sc-dWAT by mea-
suring adipose layer thickness at two anatomical locations, namely, 
in the ventral-abdominal area and the dorsal area. Subcutaneous 
adipose tissue below the skin is the major site of fat deposition, ac-
counting for approximately 50% of total body fat mass in mice (19). 
The data revealed that the subcutaneous adipose layer thickness was 
reduced by 35% at the ventral-abdominal site (P = 0.046) and 32% 
at the dorsal site (P = 0.005) in homozygous rs1421085-DEL82 rel-
ative to their homozygous controls (Fig. 2, E and F), which was in 
line with the reduction in body weight and overall fat mass mea-
sured by echo magnetic resonance imaging (echoMRI).
rs1421085-DEL82 is within a regulatory element for Irx3 
and Irx5 in mouse adipocyte progenitors
To identify the target genes under the genetic control of the rs1421085 
CRM, we examined gene expression levels of five candidate target 
genes contained within the TAD, namely, Rpgrip1l, Fto, Irx3, Irx5, 
and Irx6. Obesogenic WAT expansion is mainly regulated by hypo-
thalamic signals in the brain and WAT-intrinsic mechanisms (20), 
and both tissues have been previously implicated in the FTO obesity 
risk locus (2, 4, 6, 7). We tested target gene expression in mouse 
adipose tissue (mostly consisting of mature adipocytes) derived from 
subcutaneous inguinal WAT (sc-iWAT; a proxy for gluteofemoral 
adipose tissue in human), visceral perigonadal WAT (vc-gWAT; a 
proxy for visceral adipose tissue in human), isolated adipocyte pro-
genitors from both these adipose depots, and the hypothalamus.
We observed a decrease of Irx3 (0.65-fold, P = 0.028) and Irx5 
expression (0.71-fold, P = 0.029) in sc-iWAT–derived mouse preadi-
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Fig. 1. Evolutionary conservation of the chromatin landscape between human and mouse at the region surrounding the FTO/Fto locus. Hi-C data from human 
H1-ESC (top track) (16) and mouse embryonic stem cell (mESC) (bottom track) (74) are visualized in the 3D Genome Browser (http://3dgenome.org) (15). The heatmap 
values on a color scale correspond to the number of times that reads in two 40-kb bins were sequenced together (red, strong interaction; white, weak interaction). TADs 
are indicated at the base of the heatmaps, and the red vertical lines indicate the boundaries of the TAD containing the BMI-associated region in FTO. Histone modification 
signals (H3K27ac and H3K4me1) for human (75) and mouse (76) preadipocytes as well as DNase I hypersensitive sites (DHS) peaks for human (67) and mouse (55) adipose 
were overlapped and visualized using the 3D Genome Browser (http://3dgenome.org) (15). The blue vertical line indicates the position of BMI-associated variant 
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for rs1421085-DEL82 had an intermediate effect in Irx3 (0.81-fold, 
P = 0.0336) and Irx5 expression levels (0.79-fold, P = 0.021) (fig. 
S4A), suggesting a dose-dependent effect of rs1421085-DEL82 on 
target gene expression in sc-iWAT preadipocytes.
In contrast to the effect in sc-iWAT progenitors, we observed an 
increase of Irx3 (1.5-fold, P = 0.026) mRNA levels in vc-gWAT– 
derived mouse preadipocytes (Fig. 3B). The data further revealed a lack 
of gene expression changes in female sc-iWAT– or vc-gWAT– derived 
preadipocytes at any time point (fig. S5, A and B), which was consist-
ent with the lack of an organismal phenotype in female mutant mice 
(fig. S3). The expression of the Irx6 gene was below detection limits in 
both sc-iWAT and vc-gWAT preadipocytes. In addition, we did not 
observe any effect on Irx3 and Irx5 expression in the hypothalamus of 
male (Fig. 3C) or female animals (fig. S5C), suggesting a cell type– 
specific effect of rs1421085-DEL82 on gene expression. Last, we show 
that the rs1421085 CRM deletion did not affect Fto, Rpgrip1l, and Irx6 
gene expression levels in any tissue examined (Fig. 3, A to C, and fig. 
S5, A to C). Expression analysis of gWAT and iWAT mature adipose 
depots from homozygous male rs1421085-DEL82 and control mice 
revealed that Irx3 and Irx5 mRNA levels were not altered (fig. S4B), 
indicating that target gene expression changes and regulatory activity 
are specific to early differentiating preadipocytes.
Together, we show that out of the five potential target genes 
measured in five relevant mouse cell/tissue types, only Irx3 and Irx5 
Fig. 2. rs1421085-DEL82 results in an adipose depot–specific metabolic phenotype in mouse. (A) Schematic of the intron-1 orthologous rs1421085 region in mouse 
and the 82-nt deletion highlighted in gray. CRMs of TFBSs, conserved in 80% of human, mouse, rhesus, chimp, rabbit, rat, horse, dog, cow, and opossum species, were 
identified by scanning (+4/−8-nt windows) using Genomatix (Munich, Germany) and are highlighted in pink. (B to D) Body weight (B), fat mass (C), and lean mass (D) were 
assessed in WT and rs1421085-DEL82 mice on LFD or HFD in the same animals over a time course. Numbers for each group are male WT HFD (n = 17), rs1421085-DEL82 
HFD (n = 17), male WT LFD (n = 13), and rs1421085-DEL82 LFD (n = 15). Statistical significance was determined using two-way repeated-measures analysis of variance 
(ANOVA) and Bonferroni’s multiple comparisons test adjustment. (E and F) Skin was excised from mice on HFD at 6 months of age for histological processing. (E) Repre-
sentative histological images of dermal WAT (dWAT). (F) Relative dermal adipocyte layer (dWAT) thickness for skin samples obtained from ventral/abdominal area 
(adWAT) and the dorsal area/back (sdWAT) calculated from histological assay. Statistical significance was determined using multiple Student’s t tests. All data are expressed 
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Fig. 3. rs1421085 CRM has an adipose depot–specific effect on Irx3 and Irx5 expression in adipocytes. (A to C) Rpgrip1l, Fto, Irx3, Irx5, and Irx6 gene expression 
(qPCR) normalized to Canx in iWAT (A) and gWAT (B) preadipocytes and in hypothalamus (C) at 6 to 8 weeks. Statistical analysis using Student’s t test; means ± SEM. 
(D) Location of genes in 1.6-Mb mouse genomic locus. Tracks 4 to 7 ChromHMM (77) 3T3-L1 preadipocyte annotations (75). Track 8 ATAC-seq in iWAT preadipocytes at 
day 1 adipogenic induction. Bottom track position of FISH fosmids. (E) Representative FISH nuclei images from iWAT- and gWAT-derived male WT and rs1421085-DEL82 
undifferentiated proliferating (D0) or 1 day post-adipogenic stimulation (D1) primary preadipocytes (n = 3 animals each). Fluorescent probes for rs1421085-en, Irx3, and 
Irx5. Probe distances measured in iWAT D0 WT n = 71, rs1421085-DEL82 n = 70; iWAT D1 WT n = 90, rs1421085-DEL82 n = 90; gWAT D0 WT n = 71, rs1421085-DEL82 n = 62; 
gWAT D1 WT n = 82, rs1421085-DEL82 n = 70 nuclei. (F) Probe proximity (percentage of colocalized pairs, d < 200 nm). Statistical analysis using Fisher’s exact two-
tailed tests. (G) Violin plots (median and interquartile range) of interprobe distances (nm) between different probe combinations (rs1421085-en/Irx3; Irx3/Irx5; 
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were altered in preadipocytes of male rs1421085-DEL82 animals. 
We observed an opposite direction of target gene expression in vc-
gWAT and sc-iWAT adipocyte progenitors, which was in line with 
fat mass alterations in opposing directions. Differences in gene ex-
pression across depots could be due to either a direct effect on reg-
ulatory activity or an indirect effect on gene expression mediated by 
secondary effects independent of the rs1421085 regulatory circuitry.
To examine depot-specific spatial enhancer-promoter proximity 
between rs1421085 CRM and the target genes Irx3 and Irx5, we per-
formed three-dimensional (3D) fluorescence in situ hybridization 
(FISH) in iWAT- and gWAT-derived primary adipocyte progenitors 
of male wild-type (WT) and rs1421085-DEL82 animals. We performed 
the experiment in actively proliferating cells before confluency and 
before adipogenesis was induced (D0) and 1 day after induction of 
differentiation (D1). Fosmids that hybridize to rs1421085-en (en-
hancer element that overlaps rs1421085), Irx3, and Irx5 were used 
(Fig. 3, D and E).
In WT sc-iWAT, the Fto intron 1 rs1421085 enhancer (rs1421085-
en) and Irx3 promoter probe pairs were significantly more colocal-
ized (from 8 to 29%) and the average distance between them was 
significantly decreased (P = 0.0001), in cells induced for differentia-
tion compared to proliferating cells (D1 versus D0, respectively) 
(Fig. 3, F and G). In contrast, in rs1421085-DEL82 cells, rs1421085-en 
and Irx3 colocalization frequencies were markedly decreased and 
interprobe distances increased at D1 compared to WT cells (P = 0.0072). 
These data indicate disrupted chromosome conformation upon in-
duction of adipogenesis (Fig. 3G) that may be consistent with a de-
crease of Irx3 mRNA levels following rs1421085 CRM deletion in 
confluent sc-iWAT cells (see above, Fig. 3A). There was less probe 
colocalization (<5%) and the larger interprobe distances at both time 
points between rs1421085-en and Irx5 than was observed with Irx3, 
with no significant differences observed between genotypes (Fig. 3, 
F and G).
In vc-gWAT, probe colocalization frequencies were lower (<9%) 
and the interprobe distances were larger for rs1421085-en and Irx3 
promoter in all samples compared to sc-iWAT (Fig. 3, F and G). 
Nevertheless, we could detect increased distances between rs1421085-
en and Irx3 or Irx5 in rs1421085-DEL82 compared to WT at D0 
(P = 0.0017, rs1421085-en/Irx3; P = 0.0065, rs1421085-en/Irx5), but 
not at D1 of differentiation (Fig. 3G). The functional significance of 
these changes in chromosome conformation is unclear, as there is 
increased Irx3 mRNA levels in vc-gWAT from rs1421085-DEL82 
mice (Fig. 3B). It is possible that the increase in Irx3 expression in 
vc-gWAT could be a secondary effect rather than a direct effect of 
the genetic locus.
These data together provide evidence for dynamic chromatin 
conformation changes at the Fto/Irx3/Irx5 regulatory circuitry in 
sc-iWAT and vc-gWAT. In particular the strongly increased rs1421085-
en and Irx3 promoter spatial colocalization occurring over D0 to 
D1 of differentiation is disrupted in sc-iWAT from rs1421085-
DEL82 mice.
rs1421085 CRM controls mitochondrial copy number 
and mitochondrial function in human and mouse  
adipose-derived cells
The FTO obesity variant circuitry, mediated through IRX3 and IRX5, 
has been linked to adipocyte browning in humans and thus to mito-
chondrial function (4). Therefore, to assess the effect of rs1421085-
DEL82 on mitochondrial function and activity in WAT, we excised 
adipose tissues from male mice on an HFD. We show that adipose 
tissues from rs1421085-DEL82 mice were characterized by a signifi-
cantly increased number of mitochondria (fig. S6A) with 10.8-fold 
(P = 0.022) and 6.6-fold (P = 0.020) increase in vc-gWAT and sc-
iWAT, respectively, compared to WT animals. We next examined 
the expression of marker genes involved in thermogenesis (Adrb3, 
Pgc1a, Ucp1, Cox7a, Cox7b, Prdm16, Dio2, and Elovl3) and adipo-
genesis (Pparg, Cebpa, Fabp4, Plin1, and Fasn). We found that 
rs1421085-DEL82 resulted in a significant increase of -adrenergic 
receptor 3 (Adrb3) expression in gWAT (threefold; P < 0.0001) (fig. 
S6C) and on the browning marker Elovl3 in sc-iWAT (fig. S6D).
To assess whether gene expression changes in Adrb3 and Evolv3 
in rs1421085-DEL82 vc-gWAT and sc-iWAT had functional conse-
quences on cellular oxygen consumption rate (OCR), preadipocytes 
from WT and rs1421085-DEL82 male mice were isolated and dif-
ferentiated to perform a mitochondrial stress test using the Seahorse 
Bioflux XF24 Analyser. Under basal conditions, rs1421085-DEL82 
did not affect OCR profiles in vc-gWAT– or sc-iWAT–derived pre-
adipocytes (fig. S6B). However, -adrenergic stimulation resulted in 
significantly increasing OCR and proton leak (fig. S6B) in gWAT- 
derived rs1421085-DEL82 preadipocytes, indicative of uncoupled 
respiration in these cells. In contrast, -adrenergic stimulation in 
preadipocytes isolated from rs1421085-DEL82 iWAT had no effect 
on OCR (fig. S6B). In summary, rs1421085-DEL82 had an effect on 
mitochondrial traits, affecting slightly different mitochondrial sub-
traits across the adipose depots.
Acyl steroids in adipose are under the genetic control 
of rs1421085-DEL82 in male mice
Obesity and fat mass–related traits are associated with a dysregula-
tion in blood (21) and tissue metabolite levels (22). To link the 
rs1421085 CRM to metabolic changes in adipose, we combined our 
rs1421085 CRM deletion model on HFD with untargeted metabo-
lome analysis as an agnostic high-dimensional, high-resolution phe-
notypic readout (Fig. 4A). Untargeted metabolome analysis, which 
avoids prefiltering on selected compound features, allows to resolve 
mass to charge ratios (m/z) for a wide metabolite space, including 
metabolites of known and unknown chemical identities. We per-
formed direct-infusion ion-cyclotron-resonance Fourier transform 
mass spectrometry (DI-FT-ICR MS), known for its ultrahigh reso-
lution and accuracy, to systematically connect rs1421085 genetics 
with metabolic activity in vc-gWAT and sc-iWAT from rs1421085-
DEL82 mice (Fig. 4A). We used mass difference network (MDiN) 
analysis to assign MS features to high-confidence molecular formu-
las encompassing known and unknown metabolites (23–27). Here, 
“known metabolic features” refers to molecular formulas that have 
a match in the Human Metabolome database (HMDB) database (28). 
The data revealed that 940 of 2338 differential features matched to 
known metabolic features in sc-iWAT and 1981 of 7797 features in 
vc-gWAT when comparing rs1421085-DEL82 mutants with their con-
trols. While any assigned molecular formula can match to multiple 
isomeric compound structures and annotation is hence putative, mo-
lecular formulas are more specific for compound classes, particularly 
when distinct compound class labels are overrepresented within dif-
ferential features. To understand the causal connections between fat 
mass phenotypes (driven by the rs1421085 CRM deletion) and variation 
in metabolite levels, we performed compound class overrepresentation 
analysis (ORA) of known metabolic features that differ between the 
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m/z
Fig. 4. Metabolic profiling reveals a change of steroids in rs1421085-DEL82 male mice under HFD. (A) Experimental design. (B and C) Mass difference analysis 
(MDiA) to assign unambiguous molecular formulas and map a metabolic mass difference network (MDiN) structure to UHR-MS metabolic features (78). Mapping of HMDB 
database compounds to MDiNs shows clustering of compound classes (legend top right) on the networks of sc-iWAT (B) and vc-gWAT (C) of rs1421085-DEL82 mice. ORA 
on rs1421085-DEL82 features revealed enrichment of steroids and derivatives in sc-iWAT (P = 0.0062) and not in vc-gWAT. However, the topology of the steroid cluster in 
vc-gWAT implied high chemical diversity demanding more refined analyses. (D) A schematic of a generic biotransformation supporting (E) and (F). (E) Forward reactions 
(vertical axis) between down-regulated (consumed) source compound classes and up-regulated (produced) target compound classes on the horizontal axis. Statistical 
significance of a compound class to be over-represented as a source/target in a reaction was determined using hypergeometric test. (F) Backward reactions between 
up-regulated (produced) source compound classes and down-regulated (consumed) target compound classes. Statistical significance of a compound class to be 
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from male mice, we observed a decrease of steroids and their derivatives 
in rs1421085-DEL82 compared to WT controls (P = 0.0062) (Fig. 4B and 
table S1). We did not observe significant changes in sc-iWAT from 
females. We found an increase of glycerophospholipids (P = 0.0339) 
and a decrease in organooxygen compounds (P = 0.0255) in vc-gWAT 
from male rs1421085-DEL82 mice compared to their controls (Fig. 4C 
and table S2). Fatty acyls were strongly overrepresented among both 
increased features (P = 0.0011) and decreased features (P = 0.0053), 
indicating dynamic fatty acyl rearrangements. Steroid compounds 
did not exhibit significant enrichment within rs1421085-DEL82 vc-
gWAT from males when taking all putatively annotated metabolic 
features into account. However, steroids on the vc-gWAT MDiN 
(Fig. 4C) showed two topologies: One subset was spread over a wide 
number of edges, indicating high chemical diversity, and another 
subset was located in a dense cluster, requiring more refined analy-
ses. We observed a strong decrease of glycerolipids (P = 0.00001) in 
rs1421085-DEL82 female mice (table S3). To evaluate whether ste-
roid homeostasis, which we observed to be altered in sc-iWAT, is 
perturbed in vc-gWAT as well (and might be missed in the ORA anal-
ysis because ORA tests for known metabolites only), we performed 
mass difference enrichment analysis (MDEA). MDEA screens all 
pairs of MS features for mass differences of known biochemical trans-
formations. MS feature pairs connected by a biochemical transfor-
mation comprise a source node (reactant, substrate) of lower mass 
and a target node (product) of higher mass, irrespective of annotation 
status (known or unknown metabolic feature) (Fig. 4D) (30, 31). 
Last, MDEA tests whether a specific type of transformation, e.g., 
conjugation to fatty acyls or conjugation to steroid backbones, 
occurs with MS features of interest. MDEA on metabolic features 
allows to implicitly model the genotype effect on anabolic (i.e., sub-
strate node is down-regulated, while product node is up-regulated) 
and catabolic reactions (i.e., substrate node is up-regulated, while 
product node is down-regulated) (25, 32). We observed a decrease 
of long fatty acyl steroid compositions in favor of elevated levels of 
free fatty acids in vc-gWAT from male rs1421085-DEL82 mice 
compared to their littermate controls. More specifically, we ob-
served forward reactions implicating a consumption of fatty acyls, 
prenol lipids, and carboxylic acids related to the TCA (tricarboxylic 
acid cycle), carbohydrate units, and oxidative processes (Fig. 4E and 
table S4). Reverse reactions imply a production of prenol lipids as-
sociated with mass differences of fatty acids and steroids, and a con-
sumption of (i) fatty acyls and glycerolipids associated with mass 
differences of long unsaturated fatty acids, and (ii) steroids and ste-
roid relatives in association with fatty acyls, which is further sub-
stantiated by (iii) consumption of fatty acyls in association with 
steroids (Fig. 4F and table S5).
Together, these data indicate a stimulation of lipolysis, energy 
metabolism, and mobilization of fatty acids in adipose from 
rs1421085-DEL82 compared to their littermates and simultaneously 
an inhibition of acyl steroid production in rs1421085-DEL82 mice, 
pointing to a lower adipocyte lipidic esterification and lipogenesis 
state. These findings suggest that steroid and acyl steroid turnover in 
sc-iWAT and vc-gWAT is under the genetic control of rs1421085-
DEL82 in male mice.
Connecting the FTO rs1421085 genotype to a steroid 
metabotype in humans
Individual predispositions toward diseases can be determined by estab-
lishing the effects of genetically determined variants on metabolic 
phenotypes (metabotypes) (33–38). To validate the genotype- 
metabotype finding in rs1421085-DEL82 mice in humans and identify 
a metabolic pattern in blood plasma that differentiates rs1421085 
risk versus nonrisk individuals, we performed high-resolution FT-
ICR MS profiling in human blood plasma at baseline and following 
an OGTT. We chose a two-step discovery-replication scheme. For 
the discovery stage, we collected blood plasma samples from 50 
healthy male individuals from the KORA F4 cohort (39) (21 risk 
allele carriers and 29 nonrisk allele carriers) (table S6). We collected 
and profiled the samples before (Time 0h), 60 min (Time 1h) after, 
and 120 min (Time 2h) after an OGTT (40). To investigate geno-
type-dependent effects over the time course of the glucose tolerance 
test, we modeled the immediate OGTT response (which is the change 
in metabolic profiles between Time 0 and Time 1h) and the short-
term OGTT response (which is the change between Time 1h and 
Time 2h) (Fig.  5A). Following FT-ICR MS (41), we performed 
MDiN analysis (Fig. 5B) and assigned high-confidence molecular 
formulas to 8382 metabolic blood plasma features and used multi-
level partial least squares discriminant analysis (ML-PLS-DA) (42) 
on both OGTT responses (fig. S7, A to D). The immediate OGTT 
response was built on a subset of 1045 features (211 known meta-
bolic features), while the short-term OGTT response was built on 
1031 features (281 known metabolic features). To identify com-
pound classes that are under the genetic control of the rs1421085 
genotype, we performed ORA, which revealed 11 different com-
pound classes significantly contributing to both OGTT responses 
(fig. S8). These rs1421085-associated compound classes included 
steroids, amino acids, flavonoids, acyclic alkenes, carbonyl com-
pounds, fatty amides, phenylethylamines, glycerolipids, disaccha-
rides, peptides, and fatty alcohols (Fig. 5C). Notably, the class of 
steroids and steroid derivatives (table S7) showed the strongest 
effect among all for both OGTT responses and revealed an opposite 
behavior (fig. S8), with a notable increase of steroids and their de-
rivatives in risk individuals compared to nonrisk individuals in the 
immediate OGTT response and a decrease in the short-term OGTT 
response (Fig. 5D).
When we looked at individual steroid feature effects, we ob-
served a concerted strong up-regulation in the immediate OGTT 
response and down-regulation in the short-term OGTT response 
(Fig. 6A, fig. S9A, and table S7). No significant differences were ob-
served at basal condition (Time 0), which is the standard fasted state 
most commonly sampled for clinical diagnosis of diseases. A sub-
stantial amount of features of high significance could be observed in 
the immediate OGTT response (Time 1h–Time 0), both visually and 
statistically. Consequently, Time 1h displayed the resulting overall 
disbalance of steroid compounds. This trend reverted noticeably in 
the short-term OGTT response (Time 2h–Time 1h). To replicate 
these results, we recruited 326 healthy subjects from an independent 
cohort, comprising 243 risk allele carriers (78 males/165 females) 
and 83 nonrisk allele carriers (22 males/61 females) (table S8). 
Following FT-ICR MS and matrix generation, for male subjects, we 
confirmed the strong increase in steroids in the immediate OGTT 
response (putatively annotated steroids and steroid derivatives, 
HMDB V3.6) and their decrease in the short-term OGTT response 
(Fig. 6B, fig. S9B, and table S9). We did not observe a substantial 
amount of significant rs1421085-dependent features neither at base-
line (Fig. 6 and fig. S9) nor in female subjects (fig. S10 and table 
S10), supporting the context-dependent link of the rs1421085 geno-
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DISCUSSION
The FTO locus is linked to multiple obesity-related phenotypes 
through common variant association studies including BMI, fat 
mass–related traits, and basal metabolic rate, and is considered the 
strongest genetic risk locus for obesity in humans. We have previ-
ously implicated the noncoding variant rs1421085 as a causal variant 
at the FTO obesity risk locus linking rs1421085 to specific effector 
genes (IRX3 and IRX5) and their cellular functions (mitochondrial 
energy expenditure following -adrenergic receptor activation) in 
human subcutaneous adipocyte progenitors (4). Here, we present a 
murine model system, rs1421085-DEL82, to study the organismal, 
metabolic, and cellular consequences of the highly conserved CRM 
flanking the genetic variant rs1421085. We validated previously re-
ported results from human in vitro studies in the rs1421085-DEL82 
mouse model and expanded on those results by providing evidence 
for a context-dependent role of the genetic variant in adipose depots 
and established an effect on obesity-related whole-body phenotypes. 
We then used untargeted high-resolution metabolome analysis in 
adipose and plasma across mice and humans to link the genetic vari-
ant to its physiological state and conclude that the rs1421085 genetic 
variant mediates cross-species conserved changes in steroid patterns 
following nutritional challenges.
Our data show that deleting the rs1421085-conserved CRM in 
mice results in decreased Irx3 and Irx5 gene expression in iWAT 
adipocyte progenitors to roughly 70% of WT levels, consistent with 
regulatory fine-tuning of gene expression by noncoding common 
genetic variation. We note that the regulatory effect was specific for 
adipocyte progenitor cells and not visible at the tissue level, which 
harbor mostly mature differentiated adipocytes. All these results are 
consistent with previous results from in vitro human subcutaneous 
adipocyte model systems in vitro, where the rs1421085 variant was 
edited (fig. S11) (4). In those experiments, we established a chain of 
causation in human preadipocytes in vitro in which the rs1421085 
C allele (associated with increased BMI) was an active enhancer re-
sulting in increased IRX3/5, decreased mitochondrial function, and 
increased lipid accumulation. In contrast, the rs1421085 T allele 
(associated with decreased BMI) was a less active enhancer, result-
ing in decreased IRX3/5 expression, increased mitochondrial func-
tion, and decreased lipid accumulation. In line with these results, 
our rs1421085DEL82 mouse model recapitulates the effects of en-
hancer perturbation (removing the ARID5B TFBS motif rather 
than changing binding affinity). Consistent with the direction of 
effect that we observe in human preadipocytes in vitro, the directed 
perturbation of the rs1421085 flanking region in our rs1421085DEL82 
mouse model reduced interaction of this enhancer with its down-
stream target genes Irx3 and Irx5 (see FISH data; Fig. 3, E  to G). 
This loss of enhancer interaction was specific to induced adipocytes 
(day 1 of differentiation), potentially explaining the reduced Irx3 
and Irx5 gene expression found in confluent iWAT preadipocytes. 
In contrast, rs1421085DEL82 had no effect on enhancer interac-
tions with Irx3 and Irx5 on day 0 in the FISH experiments, which 
were actively proliferating cells at this stage. Thus, the effect of 
rs1421085DEL82 on enhancer interactions and gene expression of 
target genes seems to depend on the transition from proliferation to 
induction of the adipogenic program. Last, the rs1421085DEL82 
perturbation of the variant flanking regions increased mitochon-
drial content and resulted in decreased HFD induced body weight 
gain, fat mass, and skin layer thickness, recapitulating the BMI asso-
ciation in humans.
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Time 1h - Time 0 Time 2h - Time 1h
Fig. 5. Steroid-related annotations cluster on the MDiN of human plasma 
metabolic features showing concerted responses to OGTT challenge for the 
rs1421085 CC risk compared to the nonrisk genotype. (A) Experimental design. 
We examined the immediate OGTT response (the metabolic change between Time 
0 and Time 1h) and the short-term OGTT response (the metabolic change between 
Time 1h and Time 2h). We successively performed MDiN analysis once for the as-
signment of high-confidence molecular formula (MF) and once for bioinformatic 
inference, where appropriate (27, 31). (B) Example mapping of a biochemical reac-
tion (cholesterol and oleoyl-CoA (coenzyme A) react to give oleoyl-cholesterol and 
CoA) in the compositional space (i.e., masses and molecular formulas) as the prin-
ciple of MDiN. The m of 264.245316 atomic mass units (amu) is observed as oleic 
acid is condensed onto a substrate. (C) Description of the overall metabolic net-
work by MDiN analysis, colored for HMDB compound class (legend, top left) anno-
tation by exact formula matching or assignment of similar compositions (79). 
(D) To appreciate the behavior of this compound class, during the OGTT responses, 
we extracted this subnetwork from (C). We colored the nodes following up- and 
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Fig. 6. Tile maps describing the main steroid effect in male subjects in response to an OGTT for two independent clinical cohorts. (A and B) Each panel depicts a 
set of steroid-associated compositions in CHNO chemical space and the difference in responses of the corresponding compounds to an OGTT between risk-allele carriers 
versus nonrisk individuals. The left-side columns depict the immediate OGTT response (Time 1h–Time 0) and the short-term OGTT response (Time 2h–Time 1h) by means 
of a difference in average values of log2 fold changes in intensity levels. The right-side columns depict the static differences in average values of log2 intensity levels for 
each time considered. The stronger the green color of the filled circle, the higher the mean value associated with the risk group, compared to the mean value associated 
with the nonrisk group. In the opposite case, the stronger the blue color of the filled circle, the lower is the mean value. The size of the circles corresponds to a P value, 
from a two-sample Student’s t test assuming equal variance (risk and nonrisk). For P value lower than 0.05, the corresponding tiles are highlighted in yellow. (A) Tile maps 
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While we found an expected decreasing effect of rs1421085-
DEL82 on Irx3 and Irx5 gene expression in subcutaneous adipocyte 
progenitors from sc-iWAT, we observed an increasing effect on 
Irx3 gene expression in adipocyte progenitors from vc-gWAT. Two 
possible explanations are either that the rs1421085 CRM acts as an 
enhancer in subcutaneous adipocyte progenitors and a repressor 
in visceral adipocyte progenitors or, more likely, given the lower 
vc-gWAT enhancer-promoter colocalization we detect in vc-gWAT 
compared with iWAT, that Irx3 up-regulation in gWAT is not a 
direct consequence of the rs1421085 CRM but rather a secondary 
compensatory mechanism. While we observed an opposite direc-
tion of Irx3 gene regulation in visceral adipocyte progenitors, we 
note that our data indicate that cellular and steroidal metabolic 
changes were consistent across cellular and metabolic phenotypes 
in both subcutaneous and visceral adipose tissue depots, although 
we observed stronger genetically determined cellular and metabolic 
changes in subcutaneous compared to visceral adipose. It would 
have been interesting to examine expression in sc-dWAT; however, 
to maintain differentiation capacity in mouse preadipocytes, these 
cells have to be isolated from mice that are between 4 and 8 weeks of 
age, and at this age, there is very limited sc-dWAT accessible for 
dissection. The two depots used in this study are the most readily 
accessible and relatively well-defined depots, iWAT and gWAT, 
that are typically used to isolate primary preadipocytes.
Our rs1421085 CRM mouse model indicates a steroid metabo-
type under the genetic control of rs1421085 CRM in adipose. We 
confirmed this finding across two independent human cohorts, 
which provides evidence that the rs1421085 genetically determined 
steroid metabotype is evolutionarily conserved across mice and hu-
mans and detectable in both adipose and plasma. Steroid hormones 
(including but not limited to sex hormones) are small lipophilic 
molecules that circulate in the bloodstream controlling many phys-
iological functions including the balance of energy, metabolism, 
and responses to stress and feeding. Adipocytes are steroidogenic 
and known to synthesize and metabolize steroid hormones. Mito-
chondria play important roles in cholesterol homeostasis and the 
subsequent biosynthesis of steroid hormones, which can, in turn, 
regulate mitochondrial function. The production of steroids starts 
at the inner mitochondrial membrane (IMM) with the conversion 
of cholesterol to pregnenolone by the cytochrome P450 cholesterol 
side-chain cleavage enzyme (CYP11A1) (43). Increasing IRX3 has 
been associated with increasing UCP1, which is involved in white-
to-beige adipocyte conversion along with mitochondrial fission (44, 45). 
Mitochondrial fusion was, in turn, reported to be required for steroid 
biosynthesis (46), which links both steroid biosynthesis and thermo-
genesis to the same event within mitochondrial dynamics (45, 47). 
Consistently, the rs1421085-DEL82 model showed increased IRX3 
and OCR and inhibited acyl steroid production in vc-gWAT, while 
decreased IRX3 and no OCR response to -adrenergic stimulation 
were accompanied with increasing steroid levels in sc-iWAT. These 
findings are consistent with the postprandial steroid pattern responses 
in blood plasma of human risk allele carriers observed herein.
Large-scale genetic association studies connecting genetic vari-
ants to obesity, as assessed by BMI, have implicated the brain as 
primary tissue of action, and the FTO haplotype has previously 
been suggested to affect gene expression in the brain (2, 6). In this 
work, we provide confirmatory evidence that the rs1421085 regulato-
ry element links to context-dependent Irx3 and Irx5 gene expression 
in early differentiating adipocytes and affects body weight–related 
phenotypes. Noncoding variants can regulate one or more genes 
across long genomic distances, and the same allele or multiple alleles 
within a haplotype might have context-specific functions or function 
in different cell types. Because of the possibility for pleiotropic regu-
lation of multiple genes and multiple cell types at the FTO locus, 
evaluation of multiple variants, candidate genes, and cell types [i.e., 
adipose and central nervous system (CNS)] is critical to assess causal-
ity and to inform how those variants might converge on phenotypes 
that contribute to the progression of body weight gain. The FTO lo-
cus associates not only with BMI and fat mass–related traits but also 
with food preferences (48), which could be due to a direct effect of the 
genetic risk locus on gene expression in the CNS, an indirect effect 
mediated by a genetically determined metabotype as we described in 
our study, or a combination of both processes. The observed meta-
bolic features have a high probability to constitute either derivatives 
of sex hormones or derivatives of progestagens such as cortisol. The 
mass differences involved with significantly perturbed acyl steroid 
generation in rs1421085-DEL82 vc-gWAT highlighted aldosterone/
cortisol (isomeric) addition and condensation, pregnenolone deriva-
tives, and androgens. Cholesterol, corticosterone, and chenodeoxy-
cholic acid mass differences were not implied in fatty-acyl balance 
significantly. Cortisol is implied to counteract insulin action and to 
promote lipogenesis under chronic elevation in blood. A postprandi-
al increase of cortisol derivatives conditioned on reduced mitochon-
drial activity could promote a vicious circle toward obesity and 
diabetes. At the same time, our data imply that androgens are affected 
by rs1421085, and we have found responses to rs1421085  in males 
only. Sex hormones were previously shown to be implicated in eating 
behavior, food preferences, and hypothalamic body weight regula-
tion (49). The ratio of androgens to estrogens is tightly orchestrating 
the energy balance regulation, and a shift in this ratio leads to fat ac-
cumulation and body weight gain. Our data further indicate a sexual 
dimorphism of the steroid metabotype, which will need further ex-
ploration. Pronounced metabotypic patterns in blood plasma might 
facilitate risk assessment and planning of preventive strategies, such 
as paving the way for personalized diets.
Our work stresses the critical role of environment, i.e., nutrition, 
on the manifestation of a phenotype. We observed a resistance to 
weight gain conditional on HFD feeding of rs1421085-DEL82 mice, 
which is consistent with the notion that nutrition is considered to 
have the strongest environmental effect on obesity risk at the FTO 
locus (50,  51). Our work implicates a strong nutritionally influ-
enced steroid metabotype (metabolic phenotype) under the genetic 
control of rs1421085 CRM in mice on HFD and in humans follow-
ing an OGTT. Notably, the link between genotype and metabotype 
was not significant at baseline and was characterized by a dynamic 
behavior as revealed by modeling different time points following 
the OGTT in humans. This is consistent with previous reports, as 
sex hormones have been shown to underlie a dynamic nutrition- 
dependent regulation characterized by a postprandial decrease in 
healthy individuals (52).
Modeling noncoding variation in the mouse is challenging given 
the approximate 90- to 100-million-year divergence between mouse 
and human. In contrast to coding sequences, which have retained high 
sequence conservation, regulatory noncoding sequence has under-
gone a degree of evolutionary rewiring that may confound some 
cross-species comparisons (53). However, there is evidence for signif-
icant enrichment of functional GWAS variants in species-conserved 
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polymorphisms (SNPs) in the mouse (54). Furthermore, at least 
40% of enhancer predictions in the mouse are also predicted to be 
enhancers in humans, although this is likely an underestimate given 
the need to match tissue, cell type, and developmental stage to make 
accurate cross-species comparisons; thus, there will be many op-
portunities to probe human enhancer function by genetic manipu-
lation in the mouse (55). Consequently, for a proportion of species 
conserved regulatory GWAS variants in enhancers, it will likely be 
possible to model their physiological function in the mouse, as we 
demonstrate here. Engineering the rs1421085 CRM allowed us to 
establish organismal phenotypes under the genetic control of the 
variant, including HFD-induced weight gain and whole-body fat 
mass. The in vivo effect of the rs1421085 CRM deletion was more 
subtle than those reported for global and adipose-specific Irx3 or 
Fto knockout models (4, 6, 56–58), which is consistent with typically 
small effect sizes of common genetic variation and, in our study, a 
small deletion encompassing such a regulatory SNP. We observed a 
dose-dependent effect of the rs1421085-DEL82 genotype on body 
weight, fat mass gain, as well as Irx3 and Irx5 target gene expression, 
which is consistent with a dose-dependent effect of the FTO risk 
haplotype on body weight (~3 pounds per allele) (1).
Together, our data establish an evolutionary conserved rs1421085 
regulatory circuitry, which allowed us to characterize the genetic 
circuitry across multiple phenotypic scales: (i) adipocyte progenitor 
as cell types of action; (ii) Irx3 and Irx5 as effector genes; (iii) mito-
chondrial traits as cellular function; and (iv) diet-induced body 
weight gain and fat mass as organismal phenotypes. We link the 
rs1421085 circuitry to its genetically determined steroidal metabo-
type in males, which again was dependent on nutritional challenges.
MATERIALS AND METHODS
Metabolome analysis of mouse tissue
DI-FT-ICR MS measurements of mouse tissue
sc-iWAT and vc-gWAT were excised at 20 weeks of age and pre-
treated for the metabotype analysis. Mouse adipose tissue samples 
(50 mg) were placed in tubes containing ceramic beads (Tissue 
homogenizing CKMix, 2 ml, P000918-LYSKO-A, Precellys, Bertin 
Corp., Rockville, MD). One milliliter of cold methanol (−20°C) 
[LiChrosolv, hypergrade for liquid chromatography–mass spec-
trometry (LC-MS); Merck KGaA, Darmstadt, Germany] was added 
to the tissue samples followed by homogenization using the Precellys 
Evolution Homogenizer (Bertin Corp., Rockville, MD; 5800 rpm, 
2 × 15 s, 30-s pause time). The samples were centrifuged (11,292 rcf, 
10 min at 4°C), and the supernatants were collected into Eppendorf 
tubes and stored at −80°C. The extracts, diluted in methanol-water 
(50:50, v/v) by a factor of 1000, were analyzed in positive electro-
spray ionization (ESI) mode via DI-FT-ICR MS, using a Bruker 
SolariX instrument equipped with a 12-T magnet (Bruker Daltonik 
GmbH, Bremen, Germany). The instrument was externally cali-
brated by injecting a solution (10 g/ml) of arginine and observing 
corresponding peaks with m/z values equal to 175.11895 [M+H]+, 
349.23062 [2M+H]+, 523.34230 [3M+H]+, and 697.45397 [4M+H]+. 
In the experiment, the flow rate of infusion was set to 120 l/hour. 
Four hundred scans, each corresponding to 4 mega words (MWs) 
in the interval from 147.4 to 1000.0 m/z, were acquired and aver-
aged. The ion accumulation time was set to 0.7 s, and the time of 
flight to the detector was set to 1 ms. The voltages of capillary and 
spray shields were set to 3800 and −500 V, respectively. The flow 
rate of nebulizer gas was kept at 2.2 bar, and the drying gas flow rate 
was set to 4 liters/min (at a temperature of 180°C).
Ultrahigh resolution (UHR)–MS data preprocessing
FT-ICR MS spectra were collected and exported using the vendor 
software’s ftms Control 2.2.0 (Bruker Daltonik, GmbH, Bremen, 
Germany) and Data Analysis 4.4 (Bruker Daltonik, GmbH, Bremen, 
Germany), respectively. m/z peaks were picked at Signal-to-noise 
ratio (S/N) ≥ 4, and a minimum intensity of 1.5 × 106 counts was 
set. Gibbs peaks were removed by Data Analysis automatically. All 
spectra were exported as tab-separated asc files and loaded into the 
Kernel Calibrator (27). A mouse calibrant list was generated manually 
after first precalibrating representative mouse tissue spectra against 
fatty acids, followed by isotopic pattern simulation of the most 
abundant MS features. Molecular formulas that could be confirmed 
by means of isotopic fine structure were listed as appropriate. Mouse 
spectra were then subjected to the Kernel Calibrator. Kernel Calibrator 
visualizes a mass spectrum’s innate mass error distribution as a 
density surface, and a calibration function can be optimized under 
visual inspection until a representative calibration curve is built 
for each spectrum. The SD of mass error after calibration is gener-
ally found to be <100 ppb (parts per billion) at m/z < 500 and <300 
ppb at m/z < 1000. Spectra were further cleaned by removing m/z 
features whose mass defect could not be realized within the acquired 
m/z range given Carbon (C), Hydrogen (H), Nitrogen (N), Oxygen 
(O), Phosphorus (P), Sulfur (S), Sodium (Na), and z = 1.
Matrix generation
To perform peak alignment and generate data matrices for vc-gWAT 
and sc-iWAT cases, all the corresponding mass spectra were sub-
jected to an in-house written matrix generator algorithm that was 
set to align peaks within a 1-ppm error window.
Feature selection
To investigate how the presence or absence of the rs1421085-DEL82 
genotype affects WAT (vc-gWAT or sc-iWAT) and to select the 
most relevant features, we used PLS-DA. Given 7797 features for 
the vc-gWAT tissue type and 2338 features for the sc-iWAT tissue 
type, distinct gender-specific PLS-DA models on DEL82 effect were 
computed. The computation involved an iterative procedure de-
scribed by van Velzen et al. (42), where each step represents the se-
lection of a smaller feature subset and building a model on this 
subset. Before building initial PLS-DA models, the matrices were 
subjected to a filtering procedure that removed features whose in-
tensity values were present in less than 10% of the included samples. 
Each missing value was substituted by a minimal intensity value of 
the corresponding feature multiplied by 0.9. We also applied a 
logarithmic log2 transformation that approximates the distribu-
tion of the data to be normal. To assess the quality of PLS-DA 
models obtained at each step of the aforementioned workflow of 
van Velzen et al. (42), we used a sevenfold cross-validation scheme 
to estimate the values of Q2 (the cross-validated coefficient of deter-
mination R2). The PLS-DA models were decided to be final if the 
further model refinement via selecting a smaller subset of features 
did not improve the values R2 and Q2 (R2 = 0.94 and Q2 = 0.79 for 
males from vc-gWAT samples, R2 = 0.84 and Q2 = 0.32 for females 
from vc-gWAT samples, R2 = 0.98 and Q2 = 0.88 for males from 
sc-iWAT samples, and R2 = 0.97 and Q2 = 0.82 for females from 
sc-iWAT samples). All the calculations were done in MATLAB 2018b.
MDiN computation and network visualization
MDiN reconstruction. MDiNs are reconstructed as published in 
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spectrometric m/z values (metabolic features) as nodes and a list of 
mass differences for the assignment of edges that connect nodes. Mass 
differences are constructed from known biochemical reactions by 
subtracting the neutral monoisotopic mass of a substrate from the 
neutral monoisotopic mass of the corresponding reaction’s prod-
uct. The mass difference itself is then indicative of the incorporation 
of the reaction cosubstrate. Expressed in equations: given reaction 
1: m(A) + m(B) → m(C), mass = m(B) = m(C) − m(A). A pair of 
nodes xi and xj is connected by an edge corresponding to m(B) if 
|(m(xj) − m(xi)) − m(B)| < ppm(xi,xj), where ppm(xi,xj) is the mean 
of the mass measurement errors at m(xj) and m(xi). If the mass dif-
ference between the masses of xj and xi is equal to the mass differ-
ence m(b) up to a specified error, xi and xj receive an edge 
corresponding to reaction 1. Each assignment of a mass difference 
edge to a pair of nodes places a reaction hypothesis on the nodes. 
Herein, the mass differences from (25) were augmented with ste-
roid conjugations (condensations and additions thereof), yielding a 
set of 487 mass differences. Constructed MDiNs are used for both 
molecular formula assignment and data visualization.
MDiN visualization. Visualizations of MDiNs were performed 
using Gephi 0.9.2. Networks too dense for visual interpretation are 
pruned by omitting edges that are not of statistical relevance. MDEA 
selects mass differences associated with node sets of interest, such as 
biomarker candidates or compound classes. Herein, MDiNs were 
visualized using a set of mass differences that is optimal for cluster-
ing chemical compound classes as published by Moritz et al. (25) 
and Schmitt-Kopplin et al. (59). The respective mass differences oc-
cur within compound classes at a much higher frequency than they 
do between compound classes. These mass differences separate 
compound classes optimally, enabling visual detection of biomarker 
compound class associations on an MDiN.
ORA of HMDB compound classes in mouse tissue
Given a number of instances with nonunique properties and a sub-
set from this set, the ORA discloses whether the observed subset, 
encompassing certain properties, can be obtained by a random 
sampling rather than some defined process (29). We used this 
notion to understand the general behavior of different compound 
classes, i.e., whether some compound classes have higher or lower 
prevalence in mice with the rs1421085-DEL82 genotype. For each 
of the considered adipocyte tissue types (vc-gWAT or sc-iWAT), 
the set of all features, used to build an initial PLS-DA model, repre-
sented the total number of instances for ORA and therewith the 
reference distribution of properties. The property of each instance/
feature represented a compound class assigned by the HMDB data-
base as well as the sign of the associated regression coefficient. A 
positive sign of the regression coefficient relates to the higher abun-
dance of the feature in the rs1421085-DEL82 mice, and the negative 
sign relates to the lower abundance. If no assignment was found, 
then a generic class, denoting the absence thereof, was given to the 
feature. The subset of features chosen for the final PLS-DA model 
represented the subset of instances whose distribution of properties 
was to be compared to the reference distribution introduced above. 
For each of the considered classes and its behavior, we used the hy-
pergeometric distribution to estimate the probability (P value) 
whether the corresponding number of features (or less) can be ob-
served in the subset if it was sampled randomly. P values for com-
pound class enrichment were computed for the subset of features 
chosen for the final PLS-DA model as well as for the corresponding 
subsets with positive and negative regression coefficients. For further 
investigations, we have considered only those classes whose total 
number of instances in the reference distribution was higher than 
40. All the calculations were done in MATLAB 2018b.
ORA of compound classes driven by mass difference analysis
For each of the considered adipocyte tissue types (vc-gWAT or sc-
iWAT), the ORA was extended to show which compound classes 
prevail for each mass difference type selected from the MDEA. 
Every source and target node was given the corresponding regression 
coefficient obtained from the initial PLS-DA model. Because source 
and target nodes correspond to specific features, they were assigned 
to the respective compound classes obtained from the HMDB data-
base (28). If no assignment was present, then a generic class, denot-
ing the absence thereof, was given to the source or target node. For 
each of the considered mass difference types, the total set of instanc-
es referred to all the corresponding mass differences/edges with 
constituent source and target nodes. In turn, we considered two 
subsets, where, for each mass difference type, only those mass dif-
ferences were considered that were characterized (i) by the negative 
regression coefficients for the source nodes and the positive regres-
sion coefficients for the target nodes or (ii) by the positive regres-
sion coefficients for the source nodes and the negative regression 
coefficients for the target nodes. Because a mass difference approx-
imates a real biochemical reaction, these scenarios reflect the trans-
formations happening during this process. Afterward, depending 
on the use of either the source or target nodes, we performed the 
ORA to calculate the probability (P value) to observe a specific 
number of features belonging to a certain compound class within 
the given subset. These calculations were done using the hypergeo-
metric distribution. All the calculations were done in MATLAB 
2018b and R using the ggplot2 package.
KORA F4 cohort: Population characteristics
Study samples
Subjects were recruited from the population-based KORA F4 co-
hort in the region of Augsburg, southern Germany (39). The popu-
lation sample encompassed 50 male individuals of Caucasian origin, 
aged between 35 and 67 years. The subjects were selected on the 
basis of the FTO rs1421085 SNP genotype: homozygous controls 
(TT; n = 29), heterozygous risk allele carriers (CT; n = 4), and 
homozygous risk allele carriers (CC; n = 17). All individuals under-
went OGTT, and the blood samples collected at baseline (fasting 
state, t0), 60 min (t1), and 120 min (t2) after glucose load were used 
for the metabolome analysis. Last, a set of 48 subjects sampled at three 
time points and 2 individuals sampled at two time points was analyzed 
via DI-FT-ICR MS. Anthropometric and clinical data as well as blood 
samples were available from a standard 2-hour OGTT (75 g of glucose; 
Dextro O.G.T., Roche Diagnostics, Mannheim, Germany). Details of 
the oral metabolic challenge including anthropometric and biochemical 
measurements, sample collection, and storage are described by 
Wahl et al. (40). The study was conducted in accordance with the 
Declaration of Helsinki. All the participants gave written informed 
consent, and the Ethics Committee of the Bavarian Medical Association 
(Bayerische Landesärztekammer) approved the study.
Genotyping
KORA F4 samples were genotyped for the SNP rs1421085 with a 
concordance rate of >99.5% using the MassARRAY system with 
iPLEX chemistry (Sequenom, USA), as previously described by 
Holzapfel et al. (60). All subjects′ FTO rs1421085 genotype was 
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polymerase chain reaction (PCR) primers: 5′-accatcaaagaggctgttgt-3′ 
(rs1421085_PCRfwd) and 5′-gcacccattaactcgtcatt-3′ (rs1421085_
PCRrev); sequencing primers: 5′-tgtctctaagcccaacaaac-3′ (rs1421085_
Seqfwd) and 5′-attgagccatccatcaggtt-3′ (rs1421085_Seqrev).
The PCR was performed with around 50 ng of input genomic 
DNA in a thermocycler (Biometra, Jena, Germany) as follows: 
12 min at 95°C, 50 cycles of 20 s at 95°C, 40 s at 56°C, and 90 s at 
72°C, and finally 2 min at 72°C before cooling (8).
Replication cohort: Population characteristics
Study samples
For the validation of the findings from the KORA F4 population, we 
investigated 326 volunteers (males = 100; females = 226) aged be-
tween 22 and 75 years who attended a diabetes screening between 
September 2013 and May 2016 at the Institute for Nutritional Med-
icine, University Hospital Klinikum rechts der Isar of the Technical 
University of Munich (prediabetes clinical cohort). The screening 
addressed individuals with positive family history of type 2 diabetes 
(first- and/or second-degree relatives), overweight (BMI ≥ 25 kg/
m2) or obesity (BMI ≥ 30 kg/m2), already elevated blood glucose 
levels in previous examinations, former gestational diabetes, or an 
increased German Diabetes Risk Score (61). The screening was per-
formed in accordance with the Declaration of Helsinki. All the par-
ticipants gave written informed consent, and the Ethics Committee 
at the Faculty of Medicine of the Technical University of Munich 
approved the study. The subjects were selected on the basis of the 
FTO rs1421085 SNP genotype: homozygous controls (TT; n = 83), 
heterozygous risk allele carriers (CT; n  =  162), and homozygous 
risk allele carriers (CC; n = 81).
Oral metabolic challenge
All individuals underwent a standard 2-hour OGTT (75 g of glu-
cose; Dextro O.G.T., Roche Diagnostics, Mannheim, Germany) 
starting between 8:00 a.m. and 9:00 a.m. after a 10- to 12-hour over-
night fast. Blood samples for standard laboratory measurements 
and DNA isolation were taken at baseline (fasting values, t0), 30 min, 
60 min (t1), 90 min, and 120 min (t2) after glucose load. Samples 
taken at t0, t1, and t2 were kept for metabolome analyses.
Anthropometric and clinical parameters
The standard examination program comprised anthropometric 
measurements of height (seca 213 portable stadiometer, seca GmbH, 
Hamburg, Germany), weight, and body composition (Tanita BC-418 
MA segmental body composition analyzer, Sindelfingen, Germany), 
waist and hip circumference, as well as measurement of blood pres-
sure following established protocols.
Laboratory measurements
Measurement of standard laboratory/biochemical parameters was 
performed by SYNLAB clinical laboratory service (Munich, Germany). 
Hemoglobin A1C (HBA1c), Glutamic Oxaloacetic Transaminase (GOT), 
Glutamic-Pyruvate Transaminase (GPT), Gamma-Glutamyl Trans-
peptidase (GGT), cholesterol, Triglyceride (TG), High Density Lipo-
protein (HDL), Low Density Lipoprotein (LDL), High-sensitivity 
C-reactive protein (hsCRP), and Thyroid Stimulating Hormone 
(TSH) were determined in fasting blood samples, whereas glucose 
values were determined at every sampling point. Determination of 
insulin, proinsulin, C-peptide, and nonesterified free fatty acid levels 
at all sampling points was taken over by IDM (Tübingen Germany).
Genotyping
Double-stranded DNA was isolated from EDTA full blood or buffy 
coat using the DNeasy Blood & Tissue Kit with DNeasy Mini 
spin-columns (QIAGEN, Hilden, Germany) following the manu-
facturer’s protocol. The genotyping was partially performed by 
GENEWIZ UK (Takeley, Essex, UK) and at the Broad Institute of 
Massachusetts Institute of Technology and Harvard (Cambridge, MA, 
USA). Genotyping revealed n = 243 carriers of the FTO rs1421085 
risk allele. In accordance with the discovery study, this group com-
bined/unifies n = 81 homozygous (CC) and n = 162 heterozygous 
(CT) carriers. Eighty-three subjects homozygous for the nonrisk 
allele (TT, n = 83) were considered as controls.
Metabolome analysis of human blood plasma
DI-FT-ICR MS measurements of human blood plasma
Plasma samples from a total of 376 subjects (see above for details 
and ethical approvals), from two independent cohorts, were ana-
lyzed via DI-FT-ICR MS (24, 41). Before analyses, the metabolites 
(from 50 l of blood plasma) were extracted by C18 solid-phase ex-
traction (SPE) technology, using Omix C18 100 l tips (Varian) and 
following the protocol described by Forcisi et al. (24). The extracts, 
diluted in methanol by a factor of 50, were analyzed in positive ESI 
mode via DI-FT-ICR MS, using a Bruker SolariX instrument equipped 
with a 12-T magnet (Bruker Daltonik GmbH, Bremen, Germany). 
The instrument was externally calibrated by injecting a solution of 
arginine (10 g/ml) and observing corresponding peaks with m/z 
values equal to 175.11895 [M+H]+, 349.23062 [2M+H]+, 523.34230 
[3M+H]+, and 697.45397 [4M+H]+. In the experiment, the flow 
rate of infusion was set to 120 l/hour. Four hundred scans, each 
corresponding to 4 MWs in the interval from 147.4 to 1000.0 m/z, 
were acquired and averaged. The time of accumulation ion was set 
to 0.7 s, and the time of flight to the detector was set to 1 ms. The 
voltages of capillary and spray shields were set to 3800 and −500 V, 
respectively. The flow rate of nebulizer gas was kept at 2.2 bar, and the 
drying gas flow rate was set to 4 liters/min (at a temperature of 180°C).
UHR-MS data preprocessing
FT-ICR MS spectra were collected and exported using the vendor 
software ftms Control 2.2.0 (Bruker Daltonik GmbH, Bremen, 
Germany) and Data Analysis 4.4 (Bruker Daltonik GmbH, Bremen, 
Germany), respectively. m/z peaks were picked at S/N ≥ 4, and a 
minimum intensity of 1.5 × 106 counts was set. Gibbs peaks were 
removed by Data Analysis automatically. All spectra were exported as 
tab-separated asc files and loaded into the Kernel Calibrator (27). m/z 
calibration was then performed against an in-house repository of human 
blood plasma metabolites for both cohorts. Human blood spectra were 
then subjected to the Kernel Calibrator. Kernel Calibrator visualizes 
a mass spectrum’s innate mass error distribution as a density surface, 
and a calibration function can be optimized under visual inspection 
until a representative calibration curve is built for each spectrum. 
The SD of mass error after calibration is generally found to be <100 ppb 
at m/z  <  500 and  <300 ppb at m/z < 1000. Spectra were further 
cleaned by removing m/z features whose mass defect could not be 
realized within the acquired m/z range given CHNOPS, Na, and z = 1.
Matrix generation
To perform peak alignment and generate a data matrix for the 
KORA F4 cohort, all mass spectra were subjected to an in-house 
written matrix generator algorithm that was set to align peaks with-
in a 1 ppm error window. Heavy isotopologues were detected and 
eliminated by searching for m/z features at mass spacings corre-
sponding to those of typical heavy isotopes within an error of 3 ppm 
in conjunction to a correlation coefficient, with their corresponding 
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In the replication cohort, to target the steroid-like compounds, 
the mass spectra were filtered to match the [M+H]+ and [M+Na]+ 
adducts of any compound from the HMDB database, belonging to 
the class of “steroid and steroid derivatives.” The search window 
was set to 1 ppm. The filtered mass spectra were subjected to an in-
house written matrix generator algorithm that was set to align peaks 
within a 1-ppm error window.
MDiN-based molecular formula annotation and 
network visualization
MDiN-based molecular formula assignment was performed follow-
ing Tziotis et al. (23). An MDiN was reconstructed on the data ma-
trix from the KORA F4 cohort, using 0.1-ppm edge error (the error 
for finding a positively matching m/z peak). Molecular formulas to 
be used as starting points were assigned manually following isotopic 
fine structure confirmation as described above. Molecular formulas 
were propagated from assigned starters to nonassigned m/z features 
by propagating the molecular formula difference contained in Mass 
differences (MDs) to nonassigned neighbors. Newly assigned for-
mulas were tested against the seven golden rules and a modified 
version of the senior rule. Each newly assigned molecular formula 
was checked for consistency with all other adjacent m/z features of 
the valid formula. Formulas that did not pass these tests were reset 
to zero and allowed to be reassigned. m/z features with more than 
10 unsuccessful assignment events were discarded. The mass error 
of the resulting molecular formula assignments was found to be on 
the same scale as reported above for calibration. Unassigned features 
were discarded. MDiNs were visualized as described in the “MDiN 
computation and network visualization” section describing the 
metabolome analysis of mouse data.
Feature selection
To investigate how the presence or absence of the FTO rs1421085 
SNP genotype in the KORA F4 cohort affects the outcome of the 
metabolic challenge separated by time intervals as well as to select 
the most relevant features, we used ML-PLS-DA. The method is ca-
pable of handling longitudinal data as described by van Velzen et al. 
(42). The original matrix was divided into one containing the sam-
ples from the times t0 and t1, and another containing the samples 
from the times t1 and t2. Such a division was used to investigate the 
effect of the metabolic challenge within the corresponding time frame 
(further referred to as immediate OGTT response and short-term 
OGTT response, respectively). For feature selection and the con-
struction of final ML-PLS-DA models, we followed the same work-
flow as in metabolomics analysis of mouse tissue using PLS-DA. All 
the calculations were done in MATLAB 2018b.
To select the most relevant steroid-like compounds, associated 
with the effect of FTO rs1421085 SNP genotype over OGTT chal-
lenge in the replication cohort, we targeted only those features that 
showed similar behavioral patterns as in the case of the KORA F4 
cohort. The missing values in the matrix were substituted by a min-
imal intensity value of the corresponding feature multiplied by 0.9. 
We also applied a logarithmic log2 transformation that approxi-
mates the distribution of the data to be normal. For each gender, the 
immediate and short-term response matrices were constructed as 
the difference between the corresponding time points (t1-t0 and t2-t1, 
respectively). The criterion to select a feature encompassed all 
of the following rules: (i) The median value of a feature in the 
t1-t0 matrix should be higher in FTO rs1421085 SNP carriers; 
(ii) the median value of a feature in the t2-t1 matrix should be 
lower in FTO rs1421085 SNP carriers; and (iii) the P value of a 
two-sample Student’s t test (assuming equal variance), describing the 
effect of the presence of FTO rs1421085 SNP genotype on the 
immediate or short-term OGTT response, should be lower than 0.1.
ORA of HMDB compound classes in humans
Given a number of instances with nonunique properties and a sub-
set from this set, the ORA discloses whether the observed subset can 
be obtained by a random sampling rather than some defined pro-
cess, according to the distribution of the properties in the subset 
(29). We used this notion to understand the general behavior of dif-
ferent compound classes, i.e., they increase or decrease during the 
OGTT responses. The set of all features, used to build an initial ML-
PLS-DA model, represented the total number of instances for ORA 
at each of the considered time frames. The property of each instance/
feature represented a compound class assigned by the HMDB data-
base (28) as well as the sign of the associated regression coefficient. 
The latter defines the behavior of the feature: The positive sign re-
lates to the increase, and the negative sign relates to the decrease. If 
no assignment was found, then a generic class, denoting the absence 
of thereof, was given to the feature. The subset of features chosen 
for the final ML-PLS-DA model represented the subset of instances 
whose distribution of properties was to be compared to the refer-
ence distribution introduced above. For each of the considered 
compound classes and its behavior, we used the hypergeometric 
distribution to estimate the probability (P value) whether the corre-
sponding number of features (or less) can be observed in the subset 
if it was sampled randomly. Therefore, a low probability indicates 
that the compound class is strongly associated with its increase or 
decrease during the OGTT responses. P values for compound class 
enrichment were computed for the subset of features chosen for the 
final PLS-DA model as well as for the corresponding subsets with 
positive and negative regression coefficients. All the calculations 
were done in MATLAB 2018b.
Creating boxplots for selected steroids
The selected set of features corresponding to both the KORA F4 and 
the replication cohorts was represented as five box plots depicting 
the behavior of these features at specific time points (t0, t1, and t2) as 
well as during the challenge (t1-t0 and t2-t1). Before creating box-
plots, the original matrix (characterized only by the selected set of 
features) was divided into three matrices containing the samples 
from the corresponding time point. They were logarithmically 
log2-transformed, whereas each missing value was imputed by a 
minimal intensity value of the corresponding feature multiplied by 
0.9. To create matrices representing the behavior during the chal-
lenge t1-t0 and t2-t1, we performed the subtraction of the matrices of 
the corresponding time points. Using only the selected set of fea-
tures, the boxplots were created using R and its ggplot2 package. For 
each pair describing the presence or absence of the FTO rs1421085 
SNP genotype, we used the two-sample Student’s t test with equal 
variance to calculate the associated P value.
Adipocyte precursor isolation, culture, and differentiation
Mouse adipocyte mesenchymal stem cell isolation 
and differentiation
Mouse primary adipocytes were isolated essentially as previously 
described by Church et al. (62). Briefly, individual adipose tissue 
depots were excised from 6- to 10-week-old mice and placed in 
phosphate-buffered saline (PBS). Tissues were minced and digested 
in digestion buffer [sterile Hanks’ balanced salt solution (H8264), colla-
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NJ, USA; LS004174), 3% bovine serum albumin (BSA) (with fatty 
acids)] and incubated in a 37°C water bath for 60 to 75 min with 
shaking every 10 min by hand. When digestion was complete, tubes 
were centrifuged for 3 min at 300g to separate floating mature adi-
pocytes from the supravascular fraction (SVF), containing adipo-
cyte precursors. The supernatant containing the floating adipocyte 
fraction was removed, and the cell pellet was resuspended in pre-
warmed growth medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM) GlutaMAX (#10569010 DMEM, high glucose, 
GlutaMAX Supplement, pyruvate) supplemented with 10% fetal 
bovine serum (FBS) (Gibco, 10082-147) and 1% penicillin-streptomycin 
(5000 U/ml) (Gibco, 15070063) and grown at 37°C and 5% CO2. 
The cell solution was subsequently filtered through a 40-m nylon 
mesh and plated. Growth medium was replaced the next day, and 
every 2 days from then.
For differentiation experiments, attached preadipocytes were trypsin- 
treated using TrypLE Express Enzyme (1X) (Gibco 12605-010), in-
activated with growth medium, and counted using either the Scepter 
2.0 Handheld Automated Cell Counter (Millipore) with 60-m tips 
(Millipore) or the Countess Automated Cell Counter (Thermo Fisher 
Scientific). Cells (100,000/ml) were plated and grown to confluence. 
Two days after confluence, preadipocytes were induced to differentiate 
using induction medium containing growth medium supplemented 
with 0.5 mM 3-isobutyl-1-methylxathine (IBMX) (Sigma-Aldrich, 
I5879), 1 M dexamethasone (Sigma-Aldrich, D2915), and human 
insulin (5 g/ml) (Sigma-Aldrich, I9278). On day 4 of differentia-
tion, medium was changed to maintenance medium containing 
growth medium supplemented with insulin only. Medium was 
changed every 2 days, and differentiation was completed on days 7 
to 9 after adipogenic induction.
Human subcutaneous white adipose tissue culture 
and differentiation
Human primary SVF cells were received from Y.-H. Tseng (Harvard 
Medical School, Joslin Diabetes Center, One Joslin Place, Boston, 
MA). The cells were previously isolated and immortalized from 
human subcutaneous white adipose tissue of a female subject, aged 
56 with a BMI of 30.8. Culture and differentiation were performed 
following the protocol from the originating laboratory as described 
by Xue et al. (63). Briefly, preadipocytes were cultured in DMEM 
GlutaMAX (Gibco, 10569010) supplemented with 10% FBS (Gibco, 
10082-147) and 1% penicillin-streptomycin (5000 U/ml) (Gibco, 
15070063) at 37°C and 5% CO2. For differentiation, cells were treated 
with 0.25% trypsin (Gibco) and counted using an automatic cell 
counter, and 100,000 cells per well were seeded in a 12-well plate. 
Once cells reached confluency, differentiation was induced by adding 
freshly prepared adipogenic induction medium to cells [DMEM/high 
glucose supplemented with 10% FBS, 1% penicillin-streptomycin, 
33 M biotin, 0.5 M human insulin, 17 M pantothenate, 0.1 M 
dexamethasone, 2 nM 3,3′,5-triiodo-l-thyronine (T3), 500 M IBMX, 
and 30 M indomethacin]. Induction medium was replaced 
with fresh induction medium every 3 days for 24 days, until fully 
differentiated.
Oxygen consumption measurements using seahorse 
Bioflux analyzer
Oxygen Consumption and Bioenergetics Profile was measured using 
the XF24 extracellular flux analyzer from Seahorse Bioscience. The 
protocol used in this assay was adapted from Gesta et al. (64). For 
this assay, preadipocytes were counted using the Countess (Thermo 
Fisher Scientific) and 20,000 cells per well were seeded onto seahorse 
24-well plates in 100 l of growth medium and left to adhere over-
night. The next morning, 100 l of growth medium was added to 
each well. Two or 3 days later (depending on the depot of origin/cell 
type), cells were induced to differentiate within the seahorse plate 
following the adipogenic differentiation protocol as described pre-
viously. Each cell type was run in 10 replicates, and four wells evenly 
distributed within the plate were left without cells to use for cor-
rection of temperature variation. When the cells were terminally 
differentiated at days 7 to 9 after adipogenic induction, the assay 
was performed. For isoproterenol stimulation experiments, cells 
were treated with 1 M isoproterenol (Sigma-Aldrich, I6504) over-
night (approximately 16 to 20 hours depending on time of assay) 
before the assay was performed. The evening before the assay, the 
seahorse XF-24 instrument cartridge was loaded with seahorse 
calibrant and placed in a CO2-free incubator at 37°C overnight. On 
the day of the assay, cells were washed in XF Assay Media, 2 mM 
l-glutamine, 2 mM sodium pyruvate, and 10 mM glucose (pH was 
measured and adjusted to pH 7.4 at 37°C). The Seahorse plate con-
taining the differentiated adipocytes was then incubated for at least 
1 hour at 37°C in a CO2-free incubator to allow CO2 to diffuse out 
of solution. According to the manufacturer’s protocol, the ports of the 
seahorse XF-24 analyzer cartridge were then loaded with the fol-
lowing compounds: port A: oligomycin (complex 1 inhibitor); port 
B: FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone; 
mitochondrial uncoupler); port C: rotenone and antimycin (inhibitors 
of electron transfer).
Before running the assay, the XF-24 instrument cartridge was 
calibrated. For total OCR measurements, the minimum OCR read-
ing after rotenone/antimycin A treatment was subtracted from the 
initial untreated level following the manufacturer’s protocol. To di-
rectly measure mitochondrial thermogenesis, uncoupled respira-
tion (proton leak) was measured by subtracting the minimum OCR 
level after rotenone/antimycin from the minimum level after oligo-
mycin treatment. Oxygen concentrations were measured over time 
periods of 4 min with 2-min waiting and 2-min mixing. The proto-
col for a standard bioenergetics profile is composed of basal mito-
chondrial respiration, adenosine triphosphate (ATP) turnover, proton 
leak, and mitochondrial respiratory capacity. First, OCR in basal 
conditions was determined and used to calculate the basal mito-
chondrial respiration. After this, 2 M oligomycin was injected 
from the first port to inhibit ATP synthase, resulting in an accumu-
lation of protons in the mitochondrial intermembrane space and a 
reduced activity of the electron transport chain (ETC). The result-
ing decrease in OCR reveals the respiration driving ATP synthesis 
in the cells, indicating ATP turnover. Residual oxygen consumption 
capacity can be attributed to the proton leak maintaining a minimal 
ETC and nonmitochondrial respiration. Next, 2 M of the mito-
chondrial uncoupler FCCP was injected, which results in an in-
crease in OCR as the proton gradient across the IMM is dissipated 
and ETC resumes. This measurement reflects the maximal mito-
chondrial respiratory capacity. Last, 2 M rotenone/antimycin A is 
injected to completely stop ETC activity and the OCR reading at 
this phase reflects nonmitochondrial respiration.
Gene expression
RNA isolation
Total RNA from all cells and tissues was extracted using TRIzol reagent 
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instructions. For tissues, 1 ml of TRIzol Reagent was added to 50 to 
100 mg of tissue and homogenized using ceramic beads (Precellys) 
in a Precellys-24 automated homogenizer (Precellys). For RNA 
extractions, either the RNeasy Mini Kit (Qiagen, #74106) or the 
Direct-zol RNA MiniPrep Plus Kit (Zymo Research, #R2072) was 
used. For the RNeasy Mini Kit, 200 l of chloroform per 1 ml of 
TRIzol was added and tubes were vigorously shaken for 15 s, fol-
lowed by 3-min incubation at room temperature. Tubes were then 
centrifuged at 13,000 rpm for 15 min at 4°C. Following phase sepa-
ration, the colorless upper phase containing RNA was transferred to 
a clean tube and an equal volume of 70% EtOH was added. After 
thorough mixing to precipitate the RNA, the sample was transferred 
into a RNeasy spin column and consecutive steps were following 
the manufacturer’s protocol (RNeasy Mini Kit, Qiagen, #74106). 
For deoxyribonuclease (DNase) digestion, each sample was treated 
with 10 l of DNaseI stock plus 70 l of Buffer RDD (1500 Kunitz 
units) for 15 min at room temperature (RNase-Free DNase Set, Qiagen, 
#79254). Contaminant DNA removal was performed between Buffer 
RW1 washes (350 l before and 350 l added just after genomic 
DNA digestion). Alternatively, 100% EtOH was directly added to 
the samples in TRIzol following a Direct-zol RNA MiniPrep Plus kit 
protocol (Zymo Research, #R2072). Purified RNA was quantified 
using the Epoch Microplate Spectrophotometer (BioTek).
cDNA synthesis
Complementary DNA (cDNA) synthesis was performed using the 
High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific, #4368814) according to the manufacturer’s protocol.
Quantitative reverse transcriptase–PCR
Gene expression was measured using quantitative real-time PCR 
real-time fluorescence detection. TaqMan Gene Expression Assay 
reagents and TaqMan FAM dye-labeled probes (Thermo Fisher 
Scientific) were used to set up appropriate reactions according to 
the manufacturer’s protocol, using PCR Master Mix (2×) (Thermo 
Fisher Scientific K0171) and the ABI PRISM 7500 Fast Real-Time 
PCR System (Applied Biosystems). To determine the most suitable 
housekeeping gene to use, we performed GeNORM analysis (kit from 
PrimerDesign) of 12 housekeeping genes in advance. Canx was de-
termined as the most stable gene between samples and conditions 
and used as a housekeeping gene. The following TaqMan probes were 
used (gene name, TaqMan assay, and TaqMan assay ID): Canx: 
Mm00500330_m1, Rpgrip1l: Mm00452421_m1, Fto: Mm00488755_m1, 
Irx3: Mm00500463_m1, Irx5: Mm00502107_m1, Irx6: Mm01253620_
m1, Ppargc1a: Mm01208835_m1, Ucp1: Mm01244861_m1, Cox8b: 
Mm00432648_m1, Prdm16: Mm00712556_m1, Dio2: Mm00515664_
m1, Elovl3: Mm00468164_m1, Pparg: Mm00440940_m1, Cebpa: 
Mm00514283_s1, Fabp4: Mm00445878_m1, Plin1: Mm00558672_
m1, Fasn: Mm00662319_m1, Adrb3: Mm02601819_g1, and Cox7a1: 
Mm00438297_g1.
Assay for Transposase-Accessible Chromatin  
(ATAC) sequencing
Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) 
was performed by adapting the protocol from Buenrostro et al. (65). 
Differentiating cells were lysed directly in the cell culture plate. 
Lysis buffer was added directly onto cells grown in a 12-well plate. 
Plates were incubated on ice for 10 min until cells were permea-
bilized and nuclei were released. Lysis buffer was gently pipetted 
up and down to wash nuclei off the well and transferred into a 
chilled 1.5-ml tube to create crude nuclei. Nuclei were spun down 
at 600g for 10 min at 4°C, nuclei pellets were then resuspended 
in 40 l of Tagment DNA (TD) Buffer, nuclei were counted using 
trypan blue, and a volume of 50,000 nuclei was determined. Trans-
position reaction was performed following a previously published 
protocol (65). Tagmented DNA was PCR-amplified for 11. Quality was 
assessed using the DNA1000 Chip (Applied Biosystems) and run 
on a Bioanalyzer (Applied Biosystems). The profiles showed that 
all libraries had a mean fragment size of ~190 base pairs (bp) and 
characteristic nucleosome patterning, indicating good quality of the 
libraries. Libraries were sequenced at the Wellcome Trust Centre 
for Human Genetics in Oxford on the HiSeq4000 Illumina gener-
ating 50 Mio reads/sample, 75-bp paired end. To reduce bias due to 
PCR amplification of libraries, duplicate reads were removed. Se-
quencing reads were aligned to mm10. BWA-MEM was used 
for mapping.
ATAC-seq statistical evaluation
Trimmed reads were aligned to the mm10 mouse reference genome 
using Bowtie 2 (66). Reads mapping to the mitochondrial genome and 
alternative contigs were excluded from further analysis. After removing 
reads with a mapping quality score < 30, peaks were filtered to exclude 
(67, 68) those with duplicates or that overlapped with a blacklisted 
region. We used MACS2 (69) with “--nomodel --shift -100 --extsize 
200 -q 0.05” for the detection of open chromatin. The resulting bed 
files were converted into coverage tracks (i.e., bigWig format) for 
visualization and are deposited in the Gene Expression Omnibus 
(GEO) database under accession number GSE169032.
3D FISH
Preadipocytes were isolated as described in the “Adipocyte precursor 
isolation, culture, and differentiation” section. Adipocytes were plated 
on Superfrost Plus slides (Thermo Fisher Scientific, REF J1800AMNZ) 
placed in quadriPERM dishes. Cells were either fixed 1 day after 
they attached (D0) or induced to differentiate for 2 days (D2). For 
fixation, cells were washed three times in PBS and fixed in 4% para-
formaldehyde for 10 min. After three washes in PBS, cells were per-
meabilized in 0.5% Triton X for 10 min, followed by three washes in 
PBS. Slides were then air-dried for approximately 30 min and frozen 
at −80°C. Slides were then shipped to Iain Williamson (Wendy 
Bickmore group) at The MRC Human Genetics Unit, Institute of 
Genetics and Molecular Medicine, University of Edinburgh, where 
in situ hybridization was performed with the following fosmids 
(http://bacpacresources.org): (mm9 coordinates) rs1421085-en 
(WIBR1-0590 M09) chr8: 93911541-93950923, Irx3 (WIBR1-1206E19) 
chr8: 94307305-94341470, and Irx5 (WIBR1-1060D04) chr8: 
94965335-94904882.
Briefly, between 160 and 240 ng of biotin- and digoxigenin-labeled 
and direct-labeled (Green 496 dUTP, Enzo Life Sciences) fosmid 
probes were used per slide, with 16 to 24 mg of mouse Cot1 DNA 
(Invitrogen) and 10 mg of salmon sperm DNA. EtOH was added, 
and the probe was air-dried. Hybridization mix containing deionized 
formamide, 20× SSC, 50% dextran sulfate, and Tween 20 was added 
to the probes for ~1 hour at room temperature. Slides were treated 
with ribonuclease (RNase) for 1 hour at 37°C in 2× SSC (100 g/ml) 
followed by a series of alcohol washes (70, 90, and 100%). Denaturing 
was performed by heating the samples at 70°C for 5 min and then 
for 15 min at 80°C before a second series of alcohol washes (70% ice 
cold), and slides were then left to air dry. The hybridization mix 
containing the probes was added to the slides, and the probes were 
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of washes in 2× SSC (45°C) and 0.1× SSC (60°C), slides were blocked 
in blocking buffer (4× SSC, 5% Marvel) for ~5 min. The following 
antibody dilutions were made: rhodamine anti-dig FAB fragments 
(Roche) 1:20, Texas Red anti-sheep 1:100, biotinylated anti-avidin 
(Vector) 1:100, and streptavidin Cy5 1:10.
The slides were incubated with antibody in a moistened chamber 
at 37°C for 30 to 60 min in the following order with 4× SSC/0.1% 
Tween 20 washes in between: rhodamine anti-dig (Roche, catalog 
no. 11207750910, lot 35710000), Texas Red anti-sheep (Abcam, 
catalog no. ab6745, lot GR29419-7)/streptavidin Cy5, biotinylated 
anti-avidin (Vector, catalog no. BA-0300, lot ZF-0415), and streptavidin 
Cy5 (Amersham, catalog no. PA45001, lot 17037668). For nuclear 
staining, slides were treated with 1:1000 dilution of 4′,6-diamidino- 
2-phenylindole (DAPI) (stock 50 g/ml) for 5 min before mounting 
in Vectashield under a coverslip.
Image analysis
Following procedures previously described by Williamson et al. (70), 
slides were imaged using a Photometrics CoolSNAP HQ2 CCD 
camera and a Zeiss AxioImager A1 fluorescence microscope with a 
Plan Apochromat 100× 1.4 numerical aperture (NA) objective, a 
Nikon Intensilight Mercury–based light source (Nikon UK Ltd., 
Kingston-on-Thames, UK), and either Chroma #89014ET (three-color) 
or #89000ET (four-color) single excitation and emission filters 
(Chroma Technology Corp., Rockingham, VT) with the excitation 
and emission filters installed in prior motorized filter wheels. A 
piezoelectrically driven objective mount (PIFOC model P-721, 
Physik Instrumente GmbH & Co., Karlsruhe) was used to control 
movement in the z dimension. Step size for z stacks was set at 
0.2 mm. Hardware control, image capture, and analysis were per-
formed using Nikon Nis-Elements software (Nikon UK Ltd., Kingston- 
on-Thames, UK). Images were deconvolved using a calculated 
point spread function with the constrained iterative algorithm of 
Volocity (PerkinElmer Inc., Waltham, MA). Image analysis was 
carried out using the Quantitation module of Volocity (PerkinElmer 
Inc., Waltham, MA). For DNA FISH, only alleles with single 




All animal studies were approved by the Medical Research Council 
Harwell Institute Animal Welfare and Ethical Review Board, and all 
procedures were carried out within project license restrictions (PPL 
30/2642 and 30/3146) under the UK Animals (Scientific Procedures) 
Act 1986 and following the ARRIVE guidelines for animal research. 
Mice were housed according to UK Home Office welfare guidelines in 
a 12-hour light/dark cycle at a temperature of 21 ± 2°C and humidity 
of 55 ± 10%. Mice were fed ad libitum and had free access to water 
(25 ppm chlorine). The research diets used in this study are indicated 
in the figures. Mice that were used for primary preadipocyte isola-
tion were fed SDS maintenance chow (RM3, 3.6 kcal/g). The high-fat 
and low-fat research diets used for the phenotyping cohorts were 
the following matched diets from Research Diets Inc.: D12492 and 
D122450J, respectively. Cohort size was estimated from previous experi-
ments using the same tests and power calculations using G*Power 2. 
For the phenotyping cohorts, mice were weaned and randomized onto 
their respective diets at 3 weeks of age. All in vivo phenotyping was 
performed blind as was primary cell culture work, with the exception 
of the selected genotypes used in FISH and Seahorse analysis.
Genetic mouse model generation
Using CRISPR/Cas9 technology, the mouse models described in 
this study were generated by the Molecular & Cellular Biology 
group at MRC Harwell essentially as published by Mianné et al. 
(71). The aim was to create a point mutation at the mouse ortholog of 
human rs1421085, namely, to alter the T to a C, mimicking the human 
BMI risk allele, and the rs1421085-DEL82 allele was generated in the 
process as a result of nonhomologous end joining (NHEJ).
Design tool and choice of guide
Single-guide RNA (sgRNA) sequences were designed using http://
tefor.net/ (72) with the guide sequence most proximal to the intended 
change applied (5′-3′: TAATCAATACGATGCCTT, PAM sequence: 
AGG). The sgRNA applied is truncated with the intention of in-
creasing specificity for the target site.
Donor oligonucleotide template
Donor sequence templates were designed with homology arms of 
60 nt in size flanking the intended point mutation. The donor tem-
plate sequence was ordered as an Ultramer DNA oligonucleotide 
from IDT (5′-3′: TGCCCTGTGGCTGCAGCTCAGAAGGCTGC-
CCTACAAATTCTCACTAGACGCTTAATCAATGCGATG-
CCTTAGGACTCGAACTGCTACCGTAAAATCAATAT-
TACCTTTATTTTAAGTAGCA). The sequences of oligonucleotides, 
protospacers, and donor DNAs used within the examples presented 
in this study are shown as follows: reagent name 5′-3′ sequence: 
sgRNA_#1 sequence TAATCAATACGATGCCTTAGG, sgRNA_#2 
sequence AGCGTCTAGTGAGAATTTGTAGG.
Pronuclear microinjections of zygotes
Pronuclear microinjection into C57BL/6NTac embryos was per-
formed as described by Gardiner and Teboul (73). Cas9 mRNA 
(Tebu-Bio), sgRNAs, and single-stranded oligo DNA nucleotides 
(ssODN) were diluted in microinjection buffer [10 mM tris-HCl, 
0.1 mM EDTA, and 100 mM NaCl (pH7.5)] and injected using a 
FemtoJet system (Eppendorf) at concentrations of 200 or 100 ng/l, 
100 or 50 ng/l each, and 50 or 20 ng/l, respectively. Injected 
embryos were reimplanted in CD1 pseudo-pregnant female hosts, 
which were allowed to litter and rear F0 progeny. DNA for genotyping 
was derived from mouse ear clips.
Establishment of colony
Founder animals with evidence of a NHEJ allele were crossed to WT 
C57BL/6NTac animals. The rs1421085-DEL82 allele was characterized 
at the F1 generation by PCR and Sanger sequencing using the follow-
ing primers (5′-3′): Geno_FTO_rs_F1, TTCCTGAGCTAGTGT-
GTGTACC; Geno_FTO_rs_R1, GTCAGATTAAGGTGACGGGC.
Genotyping
Samples were genotyped with both WT and loss of allele mutant 
assays together with an internal control for copy counting in a qPCR 
TaqMan assay. In this assay, there were (i) universal probe and uni-
versal primer designed near the CRISPR deletion for both alleles, 
(ii) a WT-specific primer in the deletion designed for the WT allele, 
and (iii) a mutant-specific primer that bridges the junction designed 
for the CRISPR mutant allele.
The following Fto-DEL82 WT1 assay (FAM-labeled) primers were 
used: Fto-DEL82-Univ-Probe (5 nmol), CAGGAGCCAGATTGTC-
CACAGCA; Fto-DEL82-WT-R located in deletion (15 nmol), GGCT-
GCCCTACAAATTCTCACTAG; Fto-DEL82-Univ-F (15 nmol), 
CAGGCAAAAGCAAAAGGTGACATAC.
The following Fto-DEL82 MUT1 assay (FAM-labeled) prim-
ers were used: Fto-DEL82-Univ-Probe (5 nmol), CAGGAGC-
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AGGGTCAGCACAGAGATGC; Fto-DEL82-Univ-F (15 nmol), 
CAGGCAAAAGCAAAAGGTGACATAC.
See the Supplementary Materials (“Fto-DEL82 qPCR genotyping 
strategy”) for sequence alignments showing the position of the probe 
and primers in these assays.
The following Dot1l internal control (VIC-labeled) primers were 




Total body weight was measured every 2 weeks on a scale calibrated 
to 0.01 g. Body composition measurements were performed every 
2 weeks using an echo MRI (Echo-MRI-100, EchoMRI, Texas, USA). 
The readouts were total fat mass (g), lean mass (g), and free water in 
live, nonanesthetized mice.
Intraperitoneal glucose tolerance test
Intraperitoneal glucose tolerance test was performed in the morning 
after an overnight (up to 16 hours) fast. Body weight of the animals 
was measured, and a local anesthetic was administered to the mouse 
tail (EMLA cream, Eutectic mixture of Local Anaesthetics Lidocaine/
Prilocaine, AstraZeneca, UK). To establish the baseline glucose level 
at time point zero, blood glucose levels were measured using the 
handheld Alphatrak (Abbott) glucose monitor with Alphatrak strips 
(Abbott). Subsequently, 2 g of glucose per kilogram of body weight 
(20% glucose in 0.9% NaCl) was injected intraperitoneally and 
blood glucose levels were measured at 30, 60, and 120 min after 
injection. A fresh strip was used for each reading.
Retro-orbital bleed
Animals were euthanized by intraperitoneal injection of an overdose 
of anesthetic (0.2 ml of pentobarbitone) in accordance with Home 
Office procedures. Once fully anesthetized, a glass capillary was 
inserted into the anterior corner of the mouse eye to perforate the 
membrane of the retro-orbital sinus. Blood was collected from the 
capillary in Lithium-Heparin microvette tubes (CB30, Sarstedt, 
Nümbrecht, Germany). After cervical dislocation, animals were 
dissected and tissues were taken for weight, histology, and gene ex-
pression analysis.
Statistical analysis
Mouse data were analyzed using GraphPad Prism 8 Software and 
tests as indicated in the figure legends.
Human research participants
We have complied with all relevant ethical regulations.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/30/eabg0108/DC1
View/request a protocol for this paper from Bio-protocol.
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